BRNS vs. ADAG, CNTB, KNTE, CTXR, NGM, LABP, RLYB, VAXX, KZR, and CKPT
Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Adagene (ADAG), Connect Biopharma (CNTB), Kinnate Biopharma (KNTE), Citius Pharmaceuticals (CTXR), NGM Biopharmaceuticals (NGM), Landos Biopharma (LABP), Rallybio (RLYB), Vaxxinity (VAXX), Kezar Life Sciences (KZR), and Checkpoint Therapeutics (CKPT). These companies are all part of the "medical" sector.
Barinthus Biotherapeutics (NASDAQ:BRNS) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.
Barinthus Biotherapeutics has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Comparatively, Adagene has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.
Adagene's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.
Adagene received 13 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 78.26% of users gave Adagene an outperform vote.
Adagene has higher revenue and earnings than Barinthus Biotherapeutics.
In the previous week, Barinthus Biotherapeutics had 2 more articles in the media than Adagene. MarketBeat recorded 2 mentions for Barinthus Biotherapeutics and 0 mentions for Adagene. Barinthus Biotherapeutics' average media sentiment score of 0.32 beat Adagene's score of 0.00 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.
Barinthus Biotherapeutics presently has a consensus target price of $8.00, indicating a potential upside of 220.00%. Adagene has a consensus target price of $5.00, indicating a potential upside of 109.21%. Given Barinthus Biotherapeutics' higher probable upside, equities analysts plainly believe Barinthus Biotherapeutics is more favorable than Adagene.
25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Barinthus Biotherapeutics and Adagene tied by winning 7 of the 14 factors compared between the two stocks.
Get Barinthus Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Barinthus Biotherapeutics Competitors List
Related Companies and Tools
